Literature DB >> 26808393

Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia.

Sonja Boyd1, Andrea Tenca2, Kalle Jokelainen2, Harri Mustonen3, Leena Krogerus4, Johanna Arola1, Martti A Färkkilä2.   

Abstract

BACKGROUND AND STUDY AIMS: Primary sclerosing cholangitis (PSC) is associated with increased risk of biliary dysplasia and cholangiocarcinoma (CCA). The aim of this study was to evaluate the role of early endoscopic retrograde cholangiography (ERC) with systematic brush cytology to identify risk factors associated with biliary neoplasia. PATIENTS AND METHODS: Patients who were referred for their first ERC for suspicion of PSC between January 2006 and October 2011 were included in the study. Brush cytology specimens were scored as benign, suspicious, or malignant. End points were CCA, biliary dysplasia, benign histology, or benign disease course for ≥ 2 years.
RESULTS: PSC was diagnosed in 261 patients (125 men, 136 women), most of whom were asymptomatic (n = 211). Cholangiographic changes were mild in 57.1 %. Men presented with advanced disease more often than women. Brush cytology was benign in 243, suspicious in 16, and malignant in 2 patients. Follow-up completed in 249 patients indicated a benign disease course in 232 patients. Seven patients were diagnosed with CCA and eight had biliary dysplasia in the explanted liver. Thus, 15 patients had biliary neoplasia, and suspicious or malignant brush cytology had been detected in 8 of them at initial brushing. Advanced extrahepatic cholangiographic changes with elevated aminotransferases at diagnosis seemed to be associated with increased risk of biliary neoplasia.
CONCLUSIONS: Even in mostly asymptomatic patients with PSC, 42.9 % had advanced disease and 6.9 % presented with suspicious or malignant brush cytology at first ERC. Advanced extrahepatic ERC changes with elevated aminotransferases at diagnosis might be risk factors for biliary neoplasia. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26808393     DOI: 10.1055/s-0041-110792

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  10 in total

Review 1.  Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma.

Authors:  Sumera Rizvi; John Eaton; Ju Dong Yang; Vinay Chandrasekhara; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2018-06-05       Impact factor: 6.115

2.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

3.  Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia.

Authors:  Pedro Pereira; Velma Aho; Johanna Arola; Sonja Boyd; Kalle Jokelainen; Lars Paulin; Petri Auvinen; Martti Färkkilä
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

4.  Transpapillary tissue sampling of biliary strictures: balloon dilatation prior to forceps biopsy improves sensitivity and accuracy.

Authors:  Daniel Pörner; Dominik J Kaczmarek; Dominik Heling; Annekristin Hausen; Raphael Mohr; Robert Hüneburg; Hanno Matthaei; Tim R Glowka; Steffen Manekeller; Hans-Peter Fischer; Marieta Toma; Jacob Nattermann; Christian P Strassburg; Maria A Gonzalez-Carmona; Tobias J Weismüller
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

5.  Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.

Authors:  Hege Marie Vedeld; Marit M Grimsrud; Kim Andresen; Heidi D Pharo; Erik von Seth; Tom H Karlsen; Hilde Honne; Vemund Paulsen; Martti A Färkkilä; Annika Bergquist; Marine Jeanmougin; Lars Aabakken; Kirsten M Boberg; Trine Folseraas; Guro E Lind
Journal:  Hepatology       Date:  2021-12-05       Impact factor: 17.298

6.  Quantitative bile and serum proteomics for the screening and differential diagnosis of primary sclerosing cholangitis.

Authors:  Matilda Holm; Sakari Joenväärä; Mayank Saraswat; Tiialotta Tohmola; Toni Saarela; Andrea Tenca; Johanna Arola; Risto Renkonen; Martti Färkkilä
Journal:  PLoS One       Date:  2022-08-25       Impact factor: 3.752

7.  Novel histological scoring for predicting disease outcome in primary sclerosing cholangitis.

Authors:  Nelli Sjöblom; Sonja Boyd; Hannu Kautiainen; Johanna Arola; Martti Färkkilä
Journal:  Histopathology       Date:  2022-05-31       Impact factor: 7.778

Review 8.  The changing faces of cholangitis.

Authors:  Sum P Lee; Joseph R Roberts; Rahul Kuver
Journal:  F1000Res       Date:  2016-06-17

9.  Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis.

Authors:  Sonja Boyd; Marko Vannas; Kalle Jokelainen; Helena Isoniemi; Heikki Mäkisalo; Martti A Färkkilä; Johanna Arola
Journal:  World J Gastroenterol       Date:  2017-09-07       Impact factor: 5.742

Review 10.  Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Richard A Burkhart; Timothy M Pawlik
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.